ReviewJournal of inflammation research2024
Application Value of Platelet-to-Lymphocyte Ratio as a Novel Indicator in Rheumatoid Arthritis: A Review Based on Clinical Evidence.
Review in Journal of inflammation research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Article
- Inflammation-related composite indices and their association with osteoporosis and fragility fractures in rheumatoid arthritis.Arthritis research & therapy · 2026Article
- The predictive value of platelet-to-lymphocyte ratio and lymphocyte count in recurrent small intestinal hemorrhage: a retrospective cohort study.BMC gastroenterology · 2026Article
- Development of EL/PLGA nanoparticles for oral delivery of methotrexate with enhanced bioavailability and reduced toxicity.Drug delivery and translational research · 2026Article
- Non-linear association of admission platelet-to-lymphocyte ratio with 28- and 90-day mortality in critically ill patients with rheumatoid arthritis: a retrospective cohort study.Clinical rheumatology · 2026Article
- Combined PLR and VAS for patient self-perception in rheumatoid arthritis: a retrospective study.Frontiers in medicine · 2026Article
- Exploring the Platelet-to-Lymphocyte Ratio for Risk Stratification in Heart Failure: A Systematic Review.Cureus · 2025Review
- Associations between systemic inflammatory biomarkers and metabolic dysfunction associated steatotic liver disease: a cross-sectional study of NHANES 2017-2020.BMC gastroenterology · 2025Article
- Neutrophil-lymphocyte and platelet-lymphocyte ratios as systemic inflammatory biomarkers for atopic dermatitis in US adults: a cross-sectional NHANES study revealing subgroup heterogeneity.Frontiers in immunology · 2025Article
- Therapeutic mechanisms of polysaccharides in the management of rheumatoid arthritis: a comprehensive review.Frontiers in immunology · 2025Review
- The Value of NLR and PLR in the Diagnosis of Rheumatoid Arthritis Combined with Interstitial Lung Disease and Assessment of Treatment Effect: A Retrospective Cohort Study.International journal of general medicine · 2025Article
- Comprehensive analysis of Pan-Immune Inflammation and all-cause mortality in rheumatoid arthritis: a database-driven approach, 1999-2018.Frontiers in immunology · 2025Article
- Development and validation of a prognostic nomogram for predicting mortality risk in adult rheumatoid arthritis: an analysis of NHANES 1999-2018 data.Frontiers in immunology · 2025Article
- Research advances of pan-immune inflammation value in rheumatoid arthritis.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is a chronically progressive autoimmune disease with increasing age-standardized prevalence and incidence of RA worldwide. Its pathological features are persistent synovitis of the joint, accompanied by the release of a large number of inflammatory cytokines and cartilage and bone destruction. RA can lead to progressive joint damage, stiffness and swelling, vascular and bone-related complications, and irreversible disability, which seriously affects patients' life treatment. Early diagnosis and treatment can enhance the quality of life of RA patients. Platelet-to-lymphocyte ratio (PLR), as a common indicator in routine blood tests, has been proposed as an indicator of systemic inflammation in recent years. Its clinical detection is less invasive, economical, rapid and simple, and has been applied to the clinical evaluation of a variety of diseases. Of note, this indicator is important in assessing disease activity in RA, co-diagnosing RA, detecting subclinical complications, and monitoring responses to anti-inflammatory therapy. Therefore, this review summarizes the relationship between PLR and RA and the relevant mechanisms, further advancing the understanding of the clinical value of PLR.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.